SurgOnc Today® is an educational podcast for cancer surgeons from the Society of Surgical Oncology. Each episode features conversations with individuals who are experts within their respective fields and are members of SSO.
Tips for Applying to a Surgical Oncology Fellowship
In this episode of SurgOnc Today®, members of the SSO Fellows and Young Attendings Subcommittee, including Emily Sturm MD, Zhi Ven Fong, MD, MPH, Allison Martin, MD, and Olga Kantor, MD, review common questions about preparing for and navigating the application process of surgical oncology fellowships.
Find the article referenced in the podcast at https://pubmed.ncbi.nlm.nih.gov/30054823/.
National Accreditation Program for Rectal Cancer: How to get it done.
In this episode of SurgOnc Today®, Antonio Picon, MD, Director of Surgical Oncology at Stamford Health and his guest Steven McClane, MD, from Cooper Health will discuss the National Accreditation Program for Rectal Cancer and how surgeons can apply, develop and maintain a rectal cancer center of excellence. Learn about the process to become accredited and take your rectal cancer program to a different level. https://www.facs.org/quality-programs/cancer/naprc
Gene Expression Profiling Technologies in Patients with Early Stage Melanoma
During this episode of SurgOnc Today, Richard White, MD, Chair of the SSO Melanoma Disease Site Work Group and Giorgos Karakousis, MD, explore the science behind gene expression profiling and its role in patients with early stage melanoma.
2020-21 Practice Changing Studies in Endocrine Surgery
In this episode Carmen Solorzano, MD, Chair of the SSO Endocrine Disease Site Work Group, Electron Kebebew, MD, and Geoffrey Young, MD, PhD, discuss two practice changing studies regarding the management of Medullary and Anaplastic Thyroid Cancer.
2020 Practice Changing Trials in Sarcoma
Recent trials in sarcoma sought to determine the impact of neoadjuvant therapies and histologic/genomically specific treatments. Valerie Grignol, MD, Gabriel R. Tinoco Suarez, MD, and Alessandro Gronchi, MD, FSSO discuss the following recent trials: The EORTC-62902:STRASS trial, the NAVIGATOR study and lastly the INVICTUS study evaluated the impact of further line therapy ripretinib, a switch-control tyrosine kinase inhibitor, on progression-free survival in advanced gastrointestinal stromal tumors.
The Evolving Role of HIPEC in Ovarian Cancer
In this episode, Peritoneal Surface Malignancy Disease Site Workgroup Member, Beth Helmink, MD, PhD, from Washington University in St. Louis, reviews recent data regarding the evolving role of HIPEC in Ovarian Cancer. Joining her for this discussion are two renowned gynecologic oncologists specializing the treatment of ovarian cancer, Willemien van Driel, MD, Netherlands Cancer Institute, and Ernst Lengyel, MD, PhD, University of Chicago.